Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
about
Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewCase files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose.Treatment dosing of low-molecular-weight heparins and the dose cap dilemma: considerations for patients in Canada.Considerations for Systemic Anticoagulation in ESRD.Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative.
P2860
Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Use of low-molecular-weight he ...... tients with renal dysfunction.
@ast
Use of low-molecular-weight he ...... tients with renal dysfunction.
@en
type
label
Use of low-molecular-weight he ...... tients with renal dysfunction.
@ast
Use of low-molecular-weight he ...... tients with renal dysfunction.
@en
prefLabel
Use of low-molecular-weight he ...... tients with renal dysfunction.
@ast
Use of low-molecular-weight he ...... tients with renal dysfunction.
@en
P2860
P356
P1433
P1476
Use of low-molecular-weight he ...... tients with renal dysfunction.
@en
P2093
Kirsten L George-Phillips
Tammy J Bungard
P2860
P304
P356
10.1592/PHCO.26.10.1479
P407
P577
2006-10-01T00:00:00Z